OGN Investors Have Opportunity to Lead Organon & Co. Securities Fraud Lawsuit

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Organon & Co. securities for the period between October 31, 2024, and April 30, 2025, alleging misleading statements regarding the company's capital allocation and dividend strategy [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Organon provided positive statements to investors while concealing material adverse facts, particularly regarding its debt reduction strategy after acquiring Dermavant, which led to a 70% decrease in the regular quarterly dividend [5]. - Investors who purchased Organon securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested parties can join the class action by visiting the provided link or contacting Phillip Kim, Esq. for more information [3][6]. - A lead plaintiff must file a motion with the court by July 22, 2025, to represent other class members in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [4]. - The firm has been recognized for its success in securities class action settlements, ranking No. 1 in 2017 and consistently in the top 4 since 2013 [4].